Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 89 articles:
HTML format



Single Articles


    October 2021
  1. GERNIER F, Ahmed-Lecheheb D, Pautier P, Floquet A, et al
    "Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovaria
    BMC Cancer. 2021;21:1147.
    PubMed     Abstract available


  2. HU X, Li D, Liang Z, Liao Y, et al
    Indirect comparison of the diagnostic performance of (18)F-FDG PET/CT and MRI in differentiating benign and malignant ovarian or adnexal tumors: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:1080.
    PubMed     Abstract available


    September 2021
  3. HASENBURG A, Eichkorn D, Vosshagen F, Obermayr E, et al
    Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
    BMC Cancer. 2021;21:1037.
    PubMed     Abstract available


  4. QIAO ZW, Jiang Y, Wang L, Wang L, et al
    LINC00852 promotes the proliferation and invasion of ovarian cancer cells by competitively binding with miR-140-3p to regulate AGTR1 expression.
    BMC Cancer. 2021;21:1004.
    PubMed     Abstract available


  5. AMAYA C, Luo S, Baigorri J, Baucells R, et al
    Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
    BMC Cancer. 2021;21:981.
    PubMed     Abstract available


    August 2021
  6. SU R, Jin C, Zhou L, Cao Y, et al
    Construction of a ceRNA network of hub genes affecting immune infiltration in ovarian cancer identified by WGCNA.
    BMC Cancer. 2021;21:970.
    PubMed     Abstract available


    July 2021
  7. WANG H, Fu Y
    NR1D1 suppressed the growth of ovarian cancer by abrogating the JAK/STAT3 signaling pathway.
    BMC Cancer. 2021;21:871.
    PubMed     Abstract available


  8. YAN X, Zhang S, Jia J, Yang J, et al
    Exploring the malnutrition status and impact of total parenteral nutrition on the outcome of patients with advanced stage ovarian cancer.
    BMC Cancer. 2021;21:799.
    PubMed     Abstract available


  9. WANG W, Zou L, Wang T, Liu Z, et al
    Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis.
    BMC Cancer. 2021;21:774.
    PubMed     Abstract available


  10. LI Y, Jaiswal SK, Kaur R, Alsaadi D, et al
    Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.
    BMC Cancer. 2021;21:768.
    PubMed     Abstract available


    June 2021
  11. HE X, Wei L, Li R, Jing S, et al
    Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study.
    BMC Cancer. 2021;21:738.
    PubMed     Abstract available


  12. KOTNIK U, Peterlin B, Lovrecic L
    Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines.
    BMC Cancer. 2021;21:665.
    PubMed     Abstract available


    May 2021
  13. HAWARDEN A, Russell B, Gee ME, Kayali F, et al
    Correction to: Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study.
    BMC Cancer. 2021;21:614.
    PubMed    


  14. WANG B, Wang S, Ren W
    Development and validation of a nomogram to predict survival outcome among epithelial ovarian cancer patients with site-distant metastases: a population-based study.
    BMC Cancer. 2021;21:609.
    PubMed     Abstract available


  15. PIROLLI R, de Alencar VTL, Estati FL, Ribeiro ARG, et al
    Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort.
    BMC Cancer. 2021;21:525.
    PubMed     Abstract available


  16. LAPKE N, Chen CH, Chang TC, Chao A, et al
    Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
    BMC Cancer. 2021;21:499.
    PubMed     Abstract available


  17. WANG C, Hu K, Deng L, He W, et al
    Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
    BMC Cancer. 2021;21:491.
    PubMed     Abstract available


  18. SHIN W, Park SY, Kang S, Lim MC, et al
    How to manage synchronous endometrial and ovarian cancer patients?
    BMC Cancer. 2021;21:489.
    PubMed     Abstract available


    April 2021
  19. LEANDERSSON P, Hogberg T, Dickman PW, Malander S, et al
    Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960-2014: A population-based cohort study.
    BMC Cancer. 2021;21:465.
    PubMed     Abstract available


  20. XUE B, Li S, Jin X, Liu L, et al
    Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
    BMC Cancer. 2021;21:452.
    PubMed     Abstract available


  21. LI S, Yang T, Xiang Y, Li X, et al
    Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary.
    BMC Cancer. 2021;21:383.
    PubMed     Abstract available


  22. HAWARDEN A, Russell B, Gee ME, Skayali F, et al
    Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study.
    BMC Cancer. 2021;21:378.
    PubMed     Abstract available


    March 2021
  23. ZHU C, Zhu J, Qian L, Liu H, et al
    Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
    BMC Cancer. 2021;21:322.
    PubMed     Abstract available


  24. TOPNO R, Singh I, Kumar M, Agarwal P, et al
    Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer.
    BMC Cancer. 2021;21:220.
    PubMed     Abstract available


    February 2021
  25. GUO J, Satoh K, Tabata S, Mori M, et al
    Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells.
    BMC Cancer. 2021;21:174.
    PubMed     Abstract available


  26. ZHANG H, Zhang K, Xu Z, Chen Z, et al
    MicroRNA-545 suppresses progression of ovarian cancer through mediating PLK1 expression by a direct binding and an indirect regulation involving KDM4B-mediated demethylation.
    BMC Cancer. 2021;21:163.
    PubMed     Abstract available


    January 2021
  27. LI J, Yue H, Yu H, Lu X, et al
    Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer.
    BMC Cancer. 2021;21:67.
    PubMed     Abstract available


  28. YAN S, Fang J, Chen Y, Xie Y, et al
    Correction to: Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
    BMC Cancer. 2021;21:55.
    PubMed    


  29. GRIMES MM, Kenney SR, Dominguez DR, Brayer KJ, et al
    The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo.
    BMC Cancer. 2021;21:40.
    PubMed     Abstract available


  30. KAYAHASHI K, Mizumoto Y, Matsuoka A, Obata T, et al
    Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
    BMC Cancer. 2021;21:32.
    PubMed     Abstract available


    December 2020
  31. KIM SI, Hwang WY, Lee M, Kim HS, et al
    Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles.
    BMC Cancer. 2020;20:1199.
    PubMed     Abstract available


  32. YAN S, Fang J, Chen Y, Xie Y, et al
    Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
    BMC Cancer. 2020;20:1205.
    PubMed     Abstract available


    November 2020
  33. TSUTSUMI M, Miura H, Inagaki H, Shinkai Y, et al
    An aggressive systemic mastocytosis preceded by ovarian dysgerminoma.
    BMC Cancer. 2020;20:1162.
    PubMed     Abstract available


    October 2020
  34. LI M, Cheng X, Rong R, Gao Y, et al
    High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
    BMC Cancer. 2020;20:1032.
    PubMed     Abstract available


  35. SONG L, Tang Z, Peng C, Yang Y, et al
    Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium.
    BMC Cancer. 2020;20:1020.
    PubMed     Abstract available


  36. JOHANSEN G, Dahm-Kahler P, Staf C, Floter Radestad A, et al
    A Swedish Nationwide prospective study of oncological and reproductive outcome following fertility-sparing surgery for treatment of early stage epithelial ovarian cancer in young women.
    BMC Cancer. 2020;20:1009.
    PubMed     Abstract available


  37. FOGG KC, Miller AE, Li Y, Flanigan W, et al
    Ovarian cancer cells direct monocyte differentiation through a non-canonical pathway.
    BMC Cancer. 2020;20:1008.
    PubMed     Abstract available


  38. STOCKLEY J, Akhand R, Kennedy A, Nyberg C, et al
    Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours.
    BMC Cancer. 2020;20:1000.
    PubMed     Abstract available


  39. HOOVER AA, Hufnagel DH, Harris W, Bullock K, et al
    Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer.
    BMC Cancer. 2020;20:970.
    PubMed     Abstract available


  40. ESCALONA RM, Bilandzic M, Western P, Kadife E, et al
    TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
    BMC Cancer. 2020;20:960.
    PubMed     Abstract available


    September 2020
  41. HU J, Jiao X, Zhu L, Guo H, et al
    Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma.
    BMC Cancer. 2020;20:938.
    PubMed     Abstract available


  42. ZHANG D, Chen X, Xia H, Wang L, et al
    Promotion of the occurrence of endometrioid carcinoma by S100 calcium binding protein P.
    BMC Cancer. 2020;20:845.
    PubMed     Abstract available


    August 2020
  43. LI N, Gou J, Li L, Ming X, et al
    Staging procedures fail to benefit women with borderline ovarian tumours who want to preserve fertility: a retrospective analysis of 448 cases.
    BMC Cancer. 2020;20:769.
    PubMed     Abstract available


  44. EL ANSARI FZ, Jouali F, Marchoudi N, Bennani MM, et al
    Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    BMC Cancer. 2020;20:747.
    PubMed     Abstract available


    July 2020
  45. GOBEL A, Zinna VM, Dell'Endice S, Jaschke N, et al
    Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.
    BMC Cancer. 2020;20:703.
    PubMed     Abstract available


  46. LI T, Wang J
    Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    BMC Cancer. 2020;20:678.
    PubMed     Abstract available


  47. FANG C, Zhang Y, Zhao L, Chen X, et al
    The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.
    BMC Cancer. 2020;20:654.
    PubMed     Abstract available


    June 2020
  48. ITO M, Kodaira T, Koide Y, Okuda T, et al
    Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal/pelvic lymph nodes: a retrospective study.
    BMC Cancer. 2020;20:540.
    PubMed     Abstract available


    May 2020
  49. TSUYOSHI H, Orisaka M, Fujita Y, Asare-Werehene M, et al
    Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer.
    BMC Cancer. 2020;20:467.
    PubMed     Abstract available


  50. CHOI J, Topouza DG, Tarnouskaya A, Nesdoly S, et al
    Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.
    BMC Cancer. 2020;20:413.
    PubMed     Abstract available


  51. VAN DER MERWE NC, Oosthuizen J, Theron M, Chong G, et al
    The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer.
    BMC Cancer. 2020;20:391.
    PubMed     Abstract available


  52. PARK SJ, Shim SH, Ji YI, Kwon SH, et al
    Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
    BMC Cancer. 2020;20:385.
    PubMed     Abstract available


  53. MALGUNDKAR SH, Burney I, Al Moundhri M, Al Kalbani M, et al
    FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and beta-catenin activity in ovarian cancer.
    BMC Cancer. 2020;20:374.
    PubMed     Abstract available


    April 2020
  54. TANABE Y, Shiraishi S, Hashimoto K, Ikeda K, et al
    Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
    BMC Cancer. 2020;20:325.
    PubMed     Abstract available


  55. LIU D, Cai J, Gao A, Wang Z, et al
    Fertility sparing surgery vs radical surgery for epithelial ovarian cancer: a meta-analysis of overall survival and disease-free survival.
    BMC Cancer. 2020;20:320.
    PubMed     Abstract available


  56. DASARI VR, Carey DJ, Gogoi R
    Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
    BMC Cancer. 2020;20:273.
    PubMed     Abstract available


    March 2020
  57. SHI J, Zhou Z, Di W, Li N, et al
    Retraction Note: Correlation of CD44v6 expression with ovarian cancer progression and recurrence.
    BMC Cancer. 2020;20:236.
    PubMed     Abstract available


  58. LI N, Gou JH, Xiong J, You JJ, et al
    HOXB4 promotes the malignant progression of ovarian cancer via DHDDS.
    BMC Cancer. 2020;20:222.
    PubMed     Abstract available


  59. SUN C, Guo E, Zhou B, Shan W, et al
    Correction to: A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients.
    BMC Cancer. 2020;20:210.
    PubMed     Abstract available


  60. EOH KJ, Kim HM, Lee JY, Kim S, et al
    Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    BMC Cancer. 2020;20:204.
    PubMed     Abstract available


  61. PRZYBYTKOWSKI E, Davis T, Hosny A, Eismann J, et al
    An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    BMC Cancer. 2020;20:197.
    PubMed     Abstract available


  62. ONWUKA JU, Okekunle AP, Olutola OM, Akpa OM, et al
    Lipid profile and risk of ovarian tumours: a meta-analysis.
    BMC Cancer. 2020;20:200.
    PubMed     Abstract available


  63. LEE YJ, Kim HS, Rim JH, Lee JY, et al
    Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.
    BMC Cancer. 2020;20:185.
    PubMed     Abstract available


    February 2020
  64. HE Y, Li T, Liu J, Ou Q, et al
    Early onset neutropenia: a useful predictor of chemosensitivity and favorable prognosis in patients with serous ovarian cancer.
    BMC Cancer. 2020;20:116.
    PubMed     Abstract available


    December 2019
  65. YUE H, Wang J, Chen R, Hou X, et al
    Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer.
    BMC Cancer. 2019;19:1266.
    PubMed     Abstract available


  66. KAJIYAMA H, Suzuki S, Yoshikawa N, Kawai M, et al
    Fertility-sparing surgery and oncologic outcome among patients with early-stage ovarian cancer ~propensity score- matched analysis~.
    BMC Cancer. 2019;19:1235.
    PubMed     Abstract available


  67. DE SABANDO AR, Lafuente EU, Garcia-Amigot F, Sanchez AA, et al
    Correction to: Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    BMC Cancer. 2019;19:1227.
    PubMed     Abstract available


  68. HAN GH, Chay DB, Nam S, Cho H, et al
    Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer.
    BMC Cancer. 2019;19:1202.
    PubMed     Abstract available


  69. DA COSTA AABA, Dos Santos ES, Cotrim DP, Pandolfi NC, et al
    Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis.
    BMC Cancer. 2019;19:1194.
    PubMed     Abstract available


    November 2019
  70. YE S, Hao X, Zhou T, Wu M, et al
    Correction to: Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion.
    BMC Cancer. 2019;19:1164.
    PubMed     Abstract available


  71. RUIZ DE SABANDO A, Urrutia Lafuente E, Garcia-Amigot F, Alonso Sanchez A, et al
    Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    BMC Cancer. 2019;19:1145.
    PubMed     Abstract available


  72. SHI J, Huo R, Li N, Li H, et al
    CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
    BMC Cancer. 2019;19:1140.
    PubMed     Abstract available


  73. MALIK MZ, Chirom K, Ali S, Ishrat R, et al
    Methodology of predicting novel key regulators in ovarian cancer network: a network theoretical approach.
    BMC Cancer. 2019;19:1129.
    PubMed     Abstract available


  74. SALLINEN H, Janhonen S, Polonen P, Niskanen H, et al
    Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma.
    BMC Cancer. 2019;19:1121.
    PubMed     Abstract available


  75. XIONG S, Mhawech-Fauceglia P, Tsao-Wei D, Roman L, et al
    Expression of the luteinizing hormone receptor (LHR) in ovarian cancer.
    BMC Cancer. 2019;19:1114.
    PubMed     Abstract available


  76. LOU L, Zhou L, Wang W, Li H, et al
    Atypical ovarian carcinoid tumor with widespread skeletal metastases: a case report of multiple endocrine neoplasia type 1 in a young woman.
    BMC Cancer. 2019;19:1107.
    PubMed     Abstract available


  77. ZHANG W, Peng P, Ou X, Shen K, et al
    Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis.
    BMC Cancer. 2019;19:1095.
    PubMed     Abstract available


  78. SUN C, Guo E, Zhou B, Shan W, et al
    A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients.
    BMC Cancer. 2019;19:1061.
    PubMed     Abstract available


  79. CODILUPI T, Taube D, Naegeli H
    CRL4 ubiquitin ligase stimulates Fanconi anemia pathway-induced single-stranded DNA-RPA signaling.
    BMC Cancer. 2019;19:1042.
    PubMed     Abstract available


  80. FUNSTON G, Van Melle M, Baun ML, Jensen H, et al
    Variation in the initial assessment and investigation for ovarian cancer in symptomatic women: a systematic review of international guidelines.
    BMC Cancer. 2019;19:1028.
    PubMed     Abstract available


    October 2019
  81. MATSUBAYASHI H, Higashigawa S, Kiyozumi Y, Horiuchi Y, et al
    Metachronous ovarian endometrioid carcinomas in a patient with a PTEN variant: case report of incidentally detected Cowden syndrome.
    BMC Cancer. 2019;19:1014.
    PubMed     Abstract available


  82. ZHANG Y, Luo G, Li M, Guo P, et al
    Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis.
    BMC Cancer. 2019;19:984.
    PubMed     Abstract available


    September 2019
  83. ENGQVIST H, Parris TZ, Kovacs A, Nemes S, et al
    Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas.
    BMC Cancer. 2019;19:928.
    PubMed     Abstract available


    August 2019
  84. AHN JI, Yoo JY, Kim TH, Kim YI, et al
    G-protein coupled receptor 64 (GPR64) acts as a tumor suppressor in endometrial cancer.
    BMC Cancer. 2019;19:810.
    PubMed     Abstract available


    July 2019
  85. WANG Y, Ren F, Song Z, Chen P, et al
    Statin use and the risk of ovarian and endometrial cancers: a meta-analysis.
    BMC Cancer. 2019;19:730.
    PubMed     Abstract available


  86. MOHAMED NE, Hay T, Reed KR, Smalley MJ, et al
    APC2 is critical for ovarian WNT signalling control, fertility and tumour suppression.
    BMC Cancer. 2019;19:677.
    PubMed     Abstract available


  87. RAYES N, Bowen DJ, Coffin T, Nebgen D, et al
    MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.
    BMC Cancer. 2019;19:648.
    PubMed     Abstract available


    June 2019
  88. STUKAN M, Badocha M, Ratajczak K
    Development and validation of a model that includes two ultrasound parameters and the plasma D-dimer level for predicting malignancy in adnexal masses: an observational study.
    BMC Cancer. 2019;19:564.
    PubMed     Abstract available


  89. TSAOUSIS GN, Papadopoulou E, Apessos A, Agiannitopoulos K, et al
    Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
    BMC Cancer. 2019;19:535.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: